A Phase 1/2 interventional study of AT101(Anti-CD19 Chimeric Antigen Receptor T cell) in B-cell Non Hodgkin Lymphoma, sponsored by AbClon. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-05-26.
Sponsored by AbClon · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of — 13 open to participants now, 26 under way, 10 of them phase 3. Lymphoma, B-Cell · Korea, Republic of.
Among the 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of, this one is the 31st largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 1/2, reaches primary completion later than 22 of the 25 other live ones, and was the 34th registered.
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →13 of the 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Australia and 9 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, Australia, Belgium and 9 more countries
Ages 65–130
AstraZeneca · Sites in Korea, Republic of, United States, Australia and 5 more countries
Ages 18+
BeOne Medicines · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Australia and 10 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 20 · Phase 3 14 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 215 across the 45 interventional studies, 92 across the 2 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 47 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with AbClon as lead sponsor.
AbClon has 1 study filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
6 of the studies in Lymphoma, B-Cell with a site in Korea, Republic of that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06047080Phase 3Hoffmann-La RocheAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | 2027-10-01 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT07101328Eli Lilly and CompanyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Determine the maximum tolerant dose (MTD) based on the safety and tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials for patients with recurrent or non-reactive B cell non-Hodgkin lymphoma (B-cell NHL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Those who have identified the following forces at the time of screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-CD19 Chimeric Antigen Receptor T cell
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
Drug pages: Isosorbide · Gossypol-acetic acid
Anti-CD19 Chimeric Antigen Receptor T cell
Also known as: AT101
Determine the maximum tolerant dose (MTD) and Recommended Phase 2 Dose (RP2D)
Phase I: Tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials
Time frame: 28 days
Overall response rate (ORR) by Independent assessment
Phase II: Proportion of subjects whose best overall response in tumor evaluation was evaluated as a complete response or a partial response
Time frame: 5 years
Overall response rate (ORR) by Investigator assessment
Proportion of subjects whose best overall response in tumor evaluation
Time frame: 5 years
Duration of overall response (DOR)
Time from first response (CR or PR) to the date of initial objectively documented progression
Time frame: 5 years
Overall survival(OS)
Time from randomization to death
Time frame: 5 years
Progression free survival (PFS)
Time from randomization to disease progression or death
Time frame: 5 years
Time to response (TTR)
Time from randomization to CR or PR
Time frame: 5 years
Event free survival (EFS)
Time from randomization to progression, subsequent chemotherapy or death
Time frame: 5 years
Incidence of adverse Event
Time frame: 5 years
Peak concentration (Cmax) of AT101
Time frame: 5 years
Area under the concentration versus time curve (AUC) of AT101
Time frame: 5 years
AT101 transgene expression
Time frame: 5 years
Replication-competent lentivirus (RCL) as Assessed by quantitative polymerase
Time frame: 5 years
Concentration of cytokines
Time frame: 5 years
CD19 expression
Time frame: 5 years
Started Mar 2022 (actual). Primary completion is estimated for Mar 2030, 96 months after the start.
Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 96 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Isosorbide · Gossypol-acetic acid